AB Science received FDA authorization to initiate Phase 1/II trial of AB8939 in the treatment of acute myeloid leukemia

NEXT STORY
Cullinan Oncology to Participate in the Evercore ISI 4th Annual HealthconX Conference
PREV STORY
Quipt Announces Execution of LOI to Acquire Leader in Comprehensive Respiratory Care Within the Long-Term Care Setting With Approximately $14 Million in Annualized Revenue and $1 Million in Net Income
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Immunicum AB (publ) Announces Upcoming Presentations and Attendances at Conferences in January and February

Press Release 22 January 2018 Immunicum AB (publ) Announces Upcoming Presentations and Attendances at ...

author_avatar
NASDAQ Market News

Scilex Announces the Availability of ZTlido™

SAN DIEGO, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Scilex Pharmaceuticals Inc. (Scilex), a subsidiary ...

author_avatar
NASDAQ Market News

Celyad Registers First Hematological Patient in  CAR-T NKR-2 THINK Trial

Opening of the hematological arm of the CAR-T NKR-2 THINK trial with first Multiple ...

author_avatar
NASDAQ Market News